BRIEF-Inhibrx To Host Webcast Presentation Of Topline Results From Its Registrational Trial Of Ozekibart (Inbrx-109) In Chondrosarcoma And To Provide Updates On Colorectal Cancer And Ewing Sarcoma Expansion Cohorts

Reuters

Oct 23

Oct 22 (Reuters) - Inhibrx Biosciences Inc INBX.O:

INHIBRX TO HOST WEBCAST PRESENTATION OF TOPLINE RESULTS FROM ITS REGISTRATIONAL TRIAL OF OZEKIBART (INBRX-109) IN CHONDROSARCOMA AND TO PROVIDE UPDATES ON COLORECTAL CANCER AND EWING SARCOMA EXPANSION COHORTS

Source text: ID:nPn45h7Hna

Further company coverage: INBX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2577731205"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577731205\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577731205?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-23 05:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577731205","market":"fut","top_or_hot":-1,"title":"BRIEF-Inhibrx To Host Webcast Presentation Of Topline Results From Its Registrational Trial Of Ozekibart (Inbrx-109) In Chondrosarcoma And To Provide Updates On Colorectal Cancer And Ewing Sarcoma Expansion Cohorts","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Inhibrx To Host Webcast Presentation Of Topline Results From Its Registrational Trial Of Ozekibart (Inbrx-109) In Chondrosarcoma And To Provide Updates On Colorectal Cancer And Ewing Sarcoma Expansion Cohorts</title></head><body><p><span>Oct 22 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/INBX\">Inhibrx Biosciences</a> Inc <span>INBX.O</span>:</p><ul><li><p>INHIBRX TO HOST WEBCAST PRESENTATION OF TOPLINE RESULTS FROM ITS REGISTRATIONAL TRIAL OF OZEKIBART (INBRX-109) IN CHONDROSARCOMA AND TO PROVIDE UPDATES ON COLORECTAL CANCER AND EWING SARCOMA EXPANSION COHORTS</p></li></ul><p>Source text: <span>ID:nPn45h7Hna</span></p><p>Further company coverage: <span>INBX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Inhibrx To Host Webcast Presentation Of Topline Results From Its Registrational Trial Of Ozekibart (Inbrx-109) In Chondrosarcoma And To Provide Updates On Colorectal Cancer And Ewing Sarcoma Expansion Cohorts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Inhibrx To Host Webcast Presentation Of Topline Results From Its Registrational Trial Of Ozekibart (Inbrx-109) In Chondrosarcoma And To Provide Updates On Colorectal Cancer And Ewing Sarcoma Expansion Cohorts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-23 05:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Inhibrx To Host Webcast Presentation Of Topline Results From Its Registrational Trial Of Ozekibart (Inbrx-109) In Chondrosarcoma And To Provide Updates On Colorectal Cancer And Ewing Sarcoma Expansion Cohorts</title></head><body><p><span>Oct 22 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/INBX\">Inhibrx Biosciences</a> Inc <span>INBX.O</span>:</p><ul><li><p>INHIBRX TO HOST WEBCAST PRESENTATION OF TOPLINE RESULTS FROM ITS REGISTRATIONAL TRIAL OF OZEKIBART (INBRX-109) IN CHONDROSARCOMA AND TO PROVIDE UPDATES ON COLORECTAL CANCER AND EWING SARCOMA EXPANSION COHORTS</p></li></ul><p>Source text: <span>ID:nPn45h7Hna</span></p><p>Further company coverage: <span>INBX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INBX","symbol_name":"Inhibrx Biosciences","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nTUA1RCHKD:1","article_id":"2577731205","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577731205","pubTimestamp":1761169033,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Inhibrx To Host Webcast Presentation Of Topline Results From Its Registrational Trial Of Ozekibart (Inbrx-109) In Chondrosarcoma And To Provide Updates On Colorectal Cancer And Ewing Sarcoma Exp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INBX":"Inhibrx Biosciences","BK4139":"生物科技"},"translate_title":"简介–Inhibrx将举办网络直播，介绍其Ozekibart(Inbrx-109)在软骨肉瘤中的注册试验的主要结果，并提供结直肠癌和尤文肉瘤扩展队列的最新情况","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INBX":0.9},"content_text":"BRIEF-Inhibrx To Host Webcast Presentation Of Topline Results From Its Registrational Trial Of Ozekibart (Inbrx-109) In Chondrosarcoma And To Provide Updates On Colorectal Cancer And Ewing Sarcoma Expansion CohortsOct 22 (Reuters) - Inhibrx Biosciences Inc INBX.O:INHIBRX TO HOST WEBCAST PRESENTATION OF TOPLINE RESULTS FROM ITS REGISTRATIONAL TRIAL OF OZEKIBART (INBRX-109) IN CHONDROSARCOMA AND TO PROVIDE UPDATES ON COLORECTAL CANCER AND EWING SARCOMA EXPANSION COHORTSSource text: ID:nPn45h7HnaFurther company coverage: INBX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}